Latest & greatest articles for Benign Prostatic Hyperplasia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Benign Prostatic Hyperplasia

21. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia Prostate artery embolisation for lower urinary Prostate artery embolisation for lower urinary tr tract symptoms caused b act symptoms caused by benign prostatic y benign prostatic h hyperplasia yperplasia Interventional procedures guidance Published: 24 April 2018 nice.org.uk/guidance/ipg611 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after (...) Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of prostate artery embolisation for benign prostatic hyperplasia is adequate to support the use of this procedure © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4provided that standard arrangements are in place for clinical governance, consent and audit. 1.2 Patient selection should be done by a urologist and an interventional radiologist

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

22. First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia. (Abstract)

First-in-man Safety and Efficacy of the ClearRing Implant for the Treatment of Benign Prostatic Hyperplasia. Although effective for benign prostatic hyperplasia (BPH), transurethral resection of the prostate (TURP) can be associated with side effects including prolonged recovery, storage and voiding symptoms, and a risk of acute urinary retention.To test a new minimally invasive device for the treatment of lower urinary tract symptoms (LUTS) due to BPH, involving implantation of a C-shaped (...) model was fitted to IPSS, the Quality of Life (QOL) scale, Benign Prostatic Hyperplasia Impact Index, maximum flow rate (Qmax), and postvoid residual volume. Statistical significance was defined as p<0.05.The average age was 71.4 yr, prostate size was 35-50cm3, and IPSS was 21.6. All procedures were successfully completed with one implant in 28 patients and two implants in one patient. No serious complications occurred. Patients experienced symptom relief by 3 mo that was sustained to 12 mo. Mean

2018 European urology focus Controlled trial quality: uncertain

23. Benign prostatic hyperplasia

Benign prostatic hyperplasia Benign prostatic hyperplasia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Benign prostatic hyperplasia Last reviewed: February 2019 Last updated: September 2018 Summary Multi-factorial involving smooth muscle hyperplasia, prostatic enlargement, and bladder dysfunction, as well as input from the central nervous system. Presents with both storage symptoms (frequency, urgency, nocturia (...) invasive therapy. Failure of medical management or renal complications are indications for surgical intervention. There are a host of procedural treatments, which have unique risk/benefit profiles for consideration. Definition Lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction due to benign prostatic hyperplasia (BPH), also known as benign prostatic enlargement (BPE), are predominantly due to 2 components: a static component related to an increase in benign prostatic tissue

2018 BMJ Best Practice

24. Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia

Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia '); } else { document.write(' '); } ACE | Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia Search > > Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benign prostatic hyperplasia - Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for the treatment of benign prostatic hyperplasia (...) Published on 2 July 2018 Guidance Recommendations The Ministry of Health's Drug Advisory Committee has recommended: Alfuzosin 10mg tablet for the treatment of benign prostatic hyperplasia. Subsidy status Alfuzosin 10mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL). SDL subsidy does not apply to tamsulosin 0.4mg tablet, dutasteride 0.5mg capsule or dutasteride 0.5mg/tamsulosin 0.4mg capsule. Factors considered to inform the recommendations for subsidy Technology evaluation Point

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

25. Male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH)

Male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible

2018 Canadian Urological Association

26. Prostate artery embolisation for benign prostatic hyperplasia

Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg T, Wild C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vreugdenburg T, Wild C. Prostate artery embolisation for benign prostatic (...) commonly reported side effects associated with PAE in all studies were minor. Currently, five RCTs are ongoing comparing PAE to TURP, the end of which is scheduled for February 2021. A new evaluation is proposed in the year 2021, if results from RCTs are available by then. Project page URL Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Arteries; Embolization, Therapeutic; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia Language Published

2017 Health Technology Assessment (HTA) Database.

27. [Diode laser vaporization in benign prostatic hyperplasia]

[Diode laser vaporization in benign prostatic hyperplasia] [Diode laser vaporization in benign prostatic hyperplasia] [Diode laser vaporization in benign prostatic hyperplasia] Virgilio S, Alcaraz A, Pichon-Riviere A, Augustovski F,García Martí S, Bardach A, Ciapponi A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Virgilio S, Alcaraz (...) A, Pichon-Riviere A, Augustovski F,García Martí S, Bardach A, Ciapponi A. [Diode laser vaporization in benign prostatic hyperplasia] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rapida No 531. 2017 Authors' conclusions Evidence of moderate quality showed that in patients with a prostate volume of less than or equal to 80 mL, diode laser vaporization when compared with other surgical techniques

2017 Health Technology Assessment (HTA) Database.

28. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms (Abstract)

A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms To evaluate the efficacy and safety of combination therapy comprising a short-acting anticholinergic, imidafenacin and an alpha-blocker compared with monotherapy with an alpha-blocker only in men with lower urinary tract symptoms (LUTS) and storage symptoms.The 12-week (...) , prospective, double-blind, randomised trial enrolled men with LUTS and storage symptom. The inclusion criteria were a total International Prostate Symptom Score (IPSS) ≥12, an IPSS question 4 score ≥2, ≥8 micturitions in 24 hours, and a prostate volume >20 mL. The primary outcome was a change in the micturition number from baseline. Bladder diary variables, Patient Perception of Intensity of Urgency Scale (PPIUS) scores, IPSS and safety were assessed.Of 260 patients screened, 221 completed the study

2017 EvidenceUpdates

29. UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia

UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia UroLift System (NeoTract Inc.) for treatment of benign prostatic hyperplasia HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. UroLift System (NeoTract Inc.) for treatment of benign (...) prostatic hyperplasia. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016 Authors' objectives Current surgical treatment of benign prostatic hyperplasia (BPH) involves a transurethral resection of the prostate (TURP) requiring general or spinal anesthesia and inpatient hospitalization. TURP is associated with measureable complications, including sexual dysfunction, ejaculatory dysfunction, erectile dysfunction, urinary incontinence, bladder neck contractures, urethral stricture

2017 Health Technology Assessment (HTA) Database.

32. Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia

Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Urolift system (NeoTract Inc.) for treatment of benign (...) prostatic hyperplasia. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Benign prostatic hyperplasia (BPH) is an enlargement or growth of the prostate that affects approximately 8 million men in the United States, including 30% of men older than 50 years of age and nearly 70% of men older than 70 years of age. The enlarged prostate restricts the urethra and applies pressure on the base of the bladder. This restriction of the urethra can result

2017 Health Technology Assessment (HTA) Database.

33. Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.

Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105. Prostate artery embolisation for benign prostatic hyperplasia - Repository of AIHTA GmbH English | Browse - - - Prostate artery embolisation for benign prostatic hyperplasia Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 933kB (...) . A new evaluation is proposed in the year 2021, if results from RCTs are available. Item Type: Decision Support Document Keywords: Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), prostate artery embolisation (PAE) Subjects: > > > > > Language: English Series Name: Decision Support Document 105 Deposited on: 17 Jul 2017 10:05 Last Modified: 15 Jul 2020 17:56 Repository Staff Only: © Copyright ,

2017 Austrian Institute of Health Technology Assessment

34. Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway Full Text available with Trip Pro

Management of lower urinary tract symptoms associated with benign prostatic hyperplasia in elderly patients with a new diagnostic, therapeutic and care pathway Benign prostatic hyperplasia (BPH) resulting in lower urinary tract symptoms (LUTS) is a widespread disease that strongly interferes with the quality of life (QoL) of elderly males. It represents a real clinical and socio-economic problem may be due to the lack of a diagnostic, therapeutic and care pathway (DTCP) tool for LUTS/BPH (...) patients) was treated without the aid of the DTCP; group B (140 patients) was treated according to the DTCP.At 1 year of follow-up, the patients of Group B compared with Group A achieved a greater and significant mean reduction in the questionnaires score (International Prostate Symptom Score, Quick prostate test and QoL) linked to a higher increase in the flowmetry parameters (Qmax) and a lower postvoid residual. Furthermore, in Group B compared to Group A, a greater improvement of hydronephrosis

2016 EvidenceUpdates Controlled trial quality: uncertain

35. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. Full Text available with Trip Pro

Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.  To estimate the risk of erectile dysfunction in men who used 5-α reductase inhibitors to treat benign prostatic hyperplasia or alopecia. Cohort studies with nested case-control analyses. UK Clinical Practice Research Datalink. Two populations of men free of risk factors for erectile dysfunction (...) and other sexual dysfunction or its treatment: men aged 40 or more with benign prostatic hyperplasia who received a prescription for a 5-α reductase inhibitor (finasteride or dutasteride) or α blocker, or both, and men aged 18-59 with alopecia. In the benign prostatic hyperplasia study, exposures were classified as 5-α reductase inhibitors only, 5-α reductase inhibitors+α blockers, or α blockers only. In the alopecia study, exposures were finasteride 1 mg or no treatment. Cases were men with a diagnosis

2016 BMJ

36. Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia

Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A,Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Gonzalez L, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A,Bardach A, Ciapponi A, López A, Rey-Ares L. Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 452. 2016 Authors' conclusions The evidence found

2016 Health Technology Assessment (HTA) Database.

37. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review

Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brasure M, MacDonald R, Dahm P, Olson CM, Nelson VA, Fink HA, Risk M, Rwabasonga B, Wilt TJ. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 178. 2016 Authors' objectives To assess the efficacy, comparative effectiveness, and adverse

2016 Health Technology Assessment (HTA) Database.

38. GreenLight XPS for treating benign prostatic hyperplasia

GreenLight XPS for treating benign prostatic hyperplasia GreenLight XPS for treating benign GreenLight XPS for treating benign prostatic h prostatic hyperplasia yperplasia Medical technologies guidance Published: 14 June 2016 nice.org.uk/guidance/mtg29 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) for treating benign prostatic hyperplasia (MTG29) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 30Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 16 System impact 16 5 Cost considerations 18 Cost evidence 18 6 Conclusions 24 7 Committee members and NICE lead team 25 Medical

2016 National Institute for Health and Clinical Excellence - Medical technologies

39. Life‐threatening urethral hemorrhage after placement of a Foley catheter in a patient with uroseptic disseminated intravascular coagulation due to chronic urinary retention induced by untreated benign prostatic hyperplasia Full Text available with Trip Pro

Life‐threatening urethral hemorrhage after placement of a Foley catheter in a patient with uroseptic disseminated intravascular coagulation due to chronic urinary retention induced by untreated benign prostatic hyperplasia A 77-year-old man with severe septic disseminated intravascular coagulation following urinary infection was transported to our hospital. He had developed urinary retention induced by untreated prostatic hyperplasia. Immediate drainage with a Foley catheter was successfully (...) carried out, but the hematuria progressed to life-threatening hemorrhage.Complete hemostasis was impossible by surgical treatment because the tissue around the prostatic urethra was very fragile and hemorrhagic. Organized treatments (continuous hemodiafiltration combined with polymyxin-B immobilized fiber column hemoperfusion and systemic treatment with antibiotics and coagulation factors) were commenced soon after the operation. The patient eventually recovered from the septic disseminated

2016 Acute medicine & surgery

40. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia UroLift for treating lower urinary tr UroLift for treating lower urinary tract act symptoms of benign prostatic symptoms of benign prostatic h hyperplasia yperplasia Medical technologies guidance Published: 16 September 2015 nice.org.uk/guidance/mtg26 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 35Contents Contents 1 Recommendations 4 2 The technology 5 Description of the technology 5 Current management 6 3 Clinical evidence 8 Summary of clinical evidence 8 4 NHS considerations 21 System impact 21 5 Cost considerations 23

2015 National Institute for Health and Clinical Excellence - Medical technologies